Erythropoietin levels and Erythroid Differentiation Parameters in Patients with Lower-Risk Myelodysplastic Syndromes

Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid diseases characterized by ineffective hematopoiesis, peripheral blood (PB) cytopenia and a tendency to evolve into acute myeloid leukemia (AML). Patients with lower risk (LR)-MDS present with moderate to severe anemia in the majority of cases, due to ineffective hematopoiesis [1,2]. Current guidelines for anemia in LR-MDS recommend treatment with erythropoiesis stimulating agents (ESA) provided that hemoglobin (Hb) levels are lower than 10  g/dl and serum erythropoietin (EPO) lower than 500 IU/L [3].

Source: Leukemia Research - July 10, 2018 Category: Hematology Authors: C. Gurnari, R. Latagliata, F. Buccisano, A. Piciocchi, S. Fenu, S. Mancini, L. Fianchi, M. Criscuolo, C. Sarlo, A. Romano, G. Falconi, P. Niscola, A. Di Veroli, M. Breccia, A. Piccioni, M.A. Aloe-Spiriti, F. Lo-Coco, M.T. Voso, on behalf of GROM-L (Gruppo Tags: Letter to the Editor Source Type: research